Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1976 1
1987 1
1989 1
1990 1
1991 2
1992 2
1995 3
1996 1
1997 2
1999 6
2001 2
2002 4
2003 2
2004 3
2005 5
2006 3
2007 8
2008 7
2009 10
2010 12
2011 17
2012 19
2013 13
2014 17
2015 17
2016 14
2017 19
2018 17
2019 27
2020 26
2021 24
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

254 results
Results by year
Filters applied: . Clear all
Page 1
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Irwin MS, et al. Among authors: naranjo a. J Clin Oncol. 2021 Oct 10;39(29):3229-3241. doi: 10.1200/JCO.21.00278. Epub 2021 Jul 28. J Clin Oncol. 2021. PMID: 34319759
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Brown CE, et al. Among authors: naranjo a. N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497. N Engl J Med. 2016. PMID: 28029927 Free PMC article. Clinical Trial.
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Brady SW, Liu Y, Ma X, Gout AM, Hagiwara K, Zhou X, Wang J, Macias M, Chen X, Easton J, Mulder HL, Rusch M, Wang L, Nakitandwe J, Lei S, Davis EM, Naranjo A, Cheng C, Maris JM, Downing JR, Cheung NV, Hogarty MD, Dyer MA, Zhang J. Brady SW, et al. Among authors: naranjo a. Nat Commun. 2020 Oct 14;11(1):5183. doi: 10.1038/s41467-020-18987-4. Nat Commun. 2020. PMID: 33056981 Free PMC article.
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: naranjo a. J Clin Oncol. 2020 Jul 1;38(19):2160-2169. doi: 10.1200/JCO.20.00203. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343642 Free PMC article. Clinical Trial.
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Park JR, et al. Among authors: naranjo a. JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642. JAMA. 2019. PMID: 31454045 Free PMC article. Clinical Trial.
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Yu AL, et al. Among authors: naranjo a. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504555 Free PMC article. Clinical Trial.
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: naranjo a. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC. Brown CE, et al. Among authors: naranjo a. Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9. Clin Cancer Res. 2015. PMID: 26059190 Free PMC article. Clinical Trial.
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Twist CJ, et al. Among authors: naranjo a. J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6. J Clin Oncol. 2019. PMID: 31386611 Free PMC article. Clinical Trial.
Toxic anterior segment syndrome: A review.
Hernandez-Bogantes E, Navas A, Naranjo A, Amescua G, Graue-Hernandez EO, Flynn HW Jr, Ahmed I. Hernandez-Bogantes E, et al. Among authors: naranjo a. Surv Ophthalmol. 2019 Jul-Aug;64(4):463-476. doi: 10.1016/j.survophthal.2019.01.009. Epub 2019 Jan 28. Surv Ophthalmol. 2019. PMID: 30703402 Review.
254 results